FDA: Invokana Diabetes Drug Increases Risk of Foot and Leg Amputations
The U.S. Food and Drug Administration (FDA) confirms the popular Johnson & Johnson (J&J) diabetes drug Invokana (Invokamet, Invokamet XR) increases the risk of foot and leg amputations in people with Type 2 diabetes. [1]
The results of 2 clinical trials showed leg and foot amputations occurred about twice as often in patients taking Invokana (generic name: canagliflozin) as those given a placebo, according to an announcement on the FDA’s website. [2]
